MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ
51.78
+1.79
+3.57%
After Hours: 50.89 -0.89 -1.71% 18:21 11/04 EST
OPEN
51.48
PREV CLOSE
49.99
HIGH
52.50
LOW
50.19
VOLUME
1.39M
TURNOVER
--
52 WEEK HIGH
64.74
52 WEEK LOW
44.12
MARKET CAP
5.02B
P/E (TTM)
-10.9085
1D
5D
1M
3M
1Y
5Y
1D
Crispr Therapeutics Price Target Raised to $90.00/Share From $88.00 by Citigroup
Dow Jones · 7h ago
Crispr Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 7h ago
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90
Benzinga · 7h ago
Crispr Therapeutics Price Target Cut to $70.00/Share From $75.00 by Wells Fargo
Dow Jones · 13h ago
Crispr Therapeutics Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 13h ago
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70
Benzinga · 13h ago
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), IDEAYA Biosciences (IDYA) and Rhythm Pharmaceuticals (RYTM)
TipRanks · 15h ago
Crispr Therapeutics price target lowered to $80 from $81 at BofA
TipRanks · 15h ago
More
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Webull offers Crispr Therapeutics AG stock information, including NASDAQ: CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.